---
title: "Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/281170300.md"
description: "Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871"
datetime: "2026-03-31T10:35:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281170300.md)
  - [en](https://longbridge.com/en/news/281170300.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281170300.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281170300.md) | [English](https://longbridge.com/en/news/281170300.md)


# Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871

Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871

### 相關股票

- [FOSUN PHARMA (02196.HK)](https://longbridge.com/zh-HK/quote/02196.HK.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [FOSUN PHARMA (600196.CN)](https://longbridge.com/zh-HK/quote/600196.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)

## 相關資訊與研究

- [Hansoh pharmaceutical says Xinyue (inebilizumab injection) granted NMPA approval for new indication](https://longbridge.com/zh-HK/news/280820343.md)
- [Shanghai Fosun Pharma says NMPA approved drug registration application for sodium thiosulfate injection](https://longbridge.com/zh-HK/news/279968282.md)
- [Shanghai Fosun Pharmaceutical posts FY net income attributable RMB 3,371 million](https://longbridge.com/zh-HK/news/280390638.md)
- [TransThera Sciences Widens Annual Loss Amid Continued R&D Spend](https://longbridge.com/zh-HK/news/281187419.md)
- [Remegen says NMPA approves clinical trial of bispecific antibody-drug conjugate RC288 for injection](https://longbridge.com/zh-HK/news/281395818.md)